Richard McCloskey

Board member at OyaGen Inc - Rochester, NY, US

Richard McCloskey's Colleagues at OyaGen Inc
Ryan Bennett

Chief Scientific Officer and Lab Director

Contact Ryan Bennett

Richard McCloskey's Contact Details
HQ
585-273-4816
Location
Malvern,Pennsylvania,19355,United States
Company
OyaGen Inc
Richard McCloskey's Company Details
OyaGen Inc logo, OyaGen Inc contact details

OyaGen Inc

Rochester, NY, US • 5 - 9 Employees
BioTech/Drugs

OYAGEN is a biotechnology company formed on September 5, 2003, for the purpose of discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. OyaGen holds exclusive rights to important technologies originating from the University of Rochester Medical Center (URMC), the Thomas Jefferson University (TJU), and Oregon Health Science Center.Over the past decade, a series of research advances have identified two families of related enzymes known as Editing Enzymes. These enzymes are endogenous cellular proteins, which chemically alter RNA or DNA molecules and thereby change the genetic code. OyaGen believes that there is a significant opportunity to "harness the editing process" to create therapies for a number of disease states. OyaGen's initial therapeutic focus is a novel approach to the treatment of Human Immunodeficiency Virus (HIV). This initial focus on HIV is driven by a series of ground breaking discoveries that:-Identified an Editing Enzyme present in immune system -Determined that HIV inhibits this Editing Enzyme as a vital part of the infection cycle -Demonstrated that allowing this Editing Enzyme to function halts HIV OyaGen will pursue several proprietary assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.OyaGen offers method development and testing as a fee-for-service to academic/educational institutions and to industry. OyaGen staff will provide expert consulting services in assay development, biochemistry, structural biology, cell biology, virology for high throughput drug discovery, drug development as well as advice in preparing federal grants.

B2B Biotechnology Healthcare Pharmaceuticals BioTech/Drugs Commercial Physical Research
Details about OyaGen Inc
Frequently Asked Questions about Richard McCloskey
Richard McCloskey currently works for OYAGEN INC..
Richard McCloskey's role at OYAGEN INC. is Board member.
Richard McCloskey's email address is ***@oyageninc.com. To view Richard McCloskey's full email address, please signup to ConnectPlex.
Richard McCloskey works in the Biotechnology industry.
Richard McCloskey's colleagues at OyaGen Inc are Tom Fitzgerald, Ryan Bennett and others.
Richard McCloskey's phone number is 585-273-4816
See more information about Richard McCloskey